Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pliant Therapeutics ( (PLRX) ) has provided an announcement.
On December 2, 2025, Pliant Therapeutics announced that its Chief Medical Officer, Dr. Éric Lefebvre, will leave the company effective December 15, 2025. Dr. Lefebvre is expected to continue as a consultant to aid in the transition of his responsibilities, which may impact the company’s operational continuity and stakeholder relations.
The most recent analyst rating on (PLRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.
Spark’s Take on PLRX Stock
According to Spark, TipRanks’ AI Analyst, PLRX is a Underperform.
Pliant Therapeutics is currently facing substantial financial difficulties, with zero revenue in 2024 and ongoing net losses. These challenges are reflected in the low financial performance score. Technical analysis shows bearish trends but hints at a potential short-term rebound. Valuation remains poor due to a negative P/E ratio and lack of dividends. Additionally, a significant workforce reduction indicates further strategic challenges. Overall, these factors contribute to a low stock score, indicating high risk and limited appeal for potential investors.
To see Spark’s full report on PLRX stock, click here.
More about Pliant Therapeutics
Pliant Therapeutics operates in the biotechnology industry, focusing on developing therapies for fibrotic diseases.
Average Trading Volume: 1,040,721
Technical Sentiment Signal: Sell
Current Market Cap: $74.35M
Find detailed analytics on PLRX stock on TipRanks’ Stock Analysis page.